We have also progressed our initiative with a major public Canadian drug company that has confirmed that they will work with us to test a series of our compounds. They are interested in both testing our claims for low dosage efficacy as well as helping us determine the “mode of action” or how our drugs actual effect sodium channels. This company has a focus on drugs that affect sodium channels. Given successful results (and we are confident) the potential for further discussions relating to a commercial relationship is likely. OB will receive the data sets that result from this testing and this will add to our understanding of the biological activity of our molecules. The absence of this data has been a limiting factor in some of our discussions with various venture capital groups. We expect that the new data will help us break down those information related barriers.